NCT05081193View on ClinicalTrials.gov

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 7, 2022

Primary Completion Date

August 4, 2025

Study Completion Date

August 4, 2025

Conditions
Prostate CancerCastration-resistant Prostate CancerMetastatic Castration-resistant Prostate Cancer
Interventions
DRUG

Testosterone Undecanoate

198mg taken twice daily

DRUG

Enzalutamide

160mg taken once daily

Trial Locations (2)

15212

Allegheny Health Network, Pittsburgh

21231

Johns Hopkins Hospital, Baltimore

Sponsors

Collaborators (1)

Clarus Therapeutics, Inc.
All Listed Sponsors
collaborator

Clarus Therapeutics, Inc.

INDUSTRY

collaborator

Allegheny Health Network

OTHER

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT05081193 - Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter